Atai Beckley N.V., the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on the stock and has a $25.00 price target.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Patrick Trucchio has given his Buy rating due to a combination of factors, primarily the strong clinical profile of BPL-003 in treatment-resistant depression and the advancing, de-risked Phase 3 program. Updated Phase 2a data show a single intranasal dose produced substantial and lasting reductions in depression scores, high response and remission rates, meaningful improvement in anhedonia, and a favorable tolerability profile, which together reinforce the drug’s durability thesis and class-leading status.
In addition, Trucchio views the FDA-aligned ReConnection Phase 3 design and Breakthrough Therapy designation as important contributors to regulatory clarity and execution confidence. His valuation, based on DCF and sum-of-the-parts methods with a high probability of success assigned to BPL-003, supports a firm value around $8.1 billion and a $25 price target, which he believes more than compensates for clinical, competitive, regulatory, and market-related risks, underpinning the Buy recommendation.
In another report released on March 9, Needham also reiterated a Buy rating on the stock with a $14.00 price target.